AbbVie RA deal: best in class – but years behind
This article was originally published in Scrip
The $840m deal AbbVie signed on 23 September with Ablynx, the Belgian "nanobody" specialist, comes after it agreed to pay up to $1.35bn to Galapagos for a similar type of deal in the same therapeutic space last year, and up to $480m to Biotest the year before. The stakes are high, and for good reason: AbbVie currently sells one of the best-selling medicines of all time, the anti-TNF biologic Humira (adalimumab; 2012 sales $9.3bn). To future-proof its market-leading position in the autoimmune space it needs to cover several bases.
You may also be interested in...
Clinical data shows Ablynx's anti-IL 6R vobarilizumab (ALX0061) to have efficacy in the same range as Roche's Actemra as a monotherapy for rheumatoid arthritis. With more data due shortly, Ablynx is confident that AbbVie will exercise its option for the product.
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.